Cannabidiol ‘almost halves’ epilepsy seizures

Cannabidiol almost halves seizure frequency in children with Dravet syndrome, according to a new study.

During the phase 3 study, 199 children with drug-resistant Dravet syndrome received 10 or 20mg/kg highly purified cannabidiol or placebo added to a median of three other anticonvulsants for 14 weeks. The mean age of the children was nine years.

The study reported that 10 and 20mg/kg cannabidiol reduced the frequency of convulsive seizures by 49 and 46 per cent respectively compared with the four-week baseline. This was statistically significant compared with the 27 per cent reduction in those taking placebo.

Cannabidiol increased the proportion of patients showing at least a halving in seizure frequency (44 and 49 per cent with 10 and 20mg/kg respectively compared with 26 per cent in the placebo group) and significantly improved total seizure frequency with reductions of 56, 47 and 30 per cent respectively.

Recommended

Oral impact

Welsh pharmacy flu jab success




This website is for healthcare professionals, people who work in pharmacy and pharmacy students. By clicking into any content, you confirm this describes you and that you agree to Pharmacy Magazine's Terms of Use and Privacy Policy.

We use essential, performance, functional and advertising cookies to give you a better web experience. Find out how to manage these cookies here. We also use Interest Based Advertising Cookies to display relevant advertisements on this and other websites based on your viewing behaviour. By clicking "Accept" you agree to the use of these Cookies and our Cookie Policy.